The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of Roche Holding and Curis' advanced basal cell carcinoma drug Erivedge as well as Astellas Pharma and Medivation's prostate cancer treatment Xtandi. Genzyme's MAC1, a tissue-engineered treatment for cartilage defects, and Vivus' erectile dysfunction drug Spedra also received approval recommendations from the panel.
EU panel supports approval of 4 new drugs
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Chief, Product Review Branch||
FDA/Center for Biologics Evaluation and Research
|Silver Spring, MD|
|Director of Clinical Research||
Regenesis Biomedical, Inc.